FDA Output, September 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in September 2026. Updated September 30.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in September 2026. Updated September 30.
We profile three MedTech Innovator accelerator companies using implanted and other devices to gather information once accessible by endoscopy only: Cyted Health, Gravitas Medical, and Plio Surgical.
Medtech investing has maintained its momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook. Excerpted from our recent feature, “As Dollars Chase AI Dream, Investors Stay Grounded.”